Skip to content

Metabolic response to medium-chain triglyceride (MCT) intake with nutritionally relevant carbohydrates in the human organism: A randomized controlled trial (C8arbo II)

Metabolic response to medium-chain triglyceride (MCT) intake with nutritionally relevant carbohydrates in the human organism: A randomized controlled trial (C8arbo II) - C8arbo II

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00037804
Enrollment
15
Registered
2025-09-03
Start date
2025-10-20
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No desease / health problem is being investigated. Investigation of the influence of MCT and different carbohydrate sources on the metabolism of healthy subjects.

Interventions

Group 1: Emulsified intervention drink consisting of water, flavoring, sweetener, medium-chain triglycerides (MCT) (0.3 g/kg body weight*), glucose (0.3 g/kg body weight). *Adaptation to 0.4 g/kg body

Sponsors

FH Münster
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: - Normal body weight (BMI = 18.5–25.0)

Exclusion criteria

Exclusion criteria: - Pregnancy/breastfeeding - Presence of a serious/chronic illness with serious health impairments (e.g., cancer, cardiovascular disease, thyroid disorders, intestinal disorders) or acute illness at the time of examination - Known metabolic disorder (e.g., lipid metabolism disorder, type 1 or 2 diabetes mellitus) - Use of medication (exception: contraceptives) - Use of MCT within the past 4 weeks - Mental or linguistic limitations - Low carb or other diets with a permanent reduction in carbohydrate intake (EFSA: at least 45 En% KH) - Diagnosed eating disorders - Whole blood donation within the last 3 months and/or blood plasma donation within the last 4 weeks before the start of the study - Intolerance to sweeteners (e.g., cyclamate, thaumatin, aspartame) - Difficult/impossible venous blood collection due to anatomical conditions or other medical reasons (e.g., veins that are difficult to locate, fragile, or severely sclerotic) - Pronounced fear of blood collection or injections

Design outcomes

Primary

MeasureTime frame
ß-hydroxybutyrate (ßHB; tmax) in venous blood, measured before the intervention (t0) and 30, 60, 120, 180, 240, and 300 minutes (t1 - t6) after the intervention. Blood is drawn using an indwelling venous catheter.

Secondary

MeasureTime frame
- Body weight measured using body scales before the intervention days - Body height measured using a stadiometer before the intervention days - Body mass index (BMI) calculated from body weight and height before the intervention days - Body composition measured using bioelectrical impedance analysis (BIA) before the intervention days - Insulin, glucose, and essential/non-essential fatty acids in venous blood, measured before the intervention (t0) and 30, 60, 120, 180, 240, and 300 minutes (t1 - t6) after the intervention - Glucose in interstitial fluid via permanent glucose sensor, continuous measurement - Glucose and ßHB in capillary blood, measured before the intervention (t0) and 30, 60, 180, and 300 minutes (t1, t2, t4, t6) after the intervention. - Ketone bodies, leukocytes, nitrite, pH, protein, glucose, urobilinogen, bilirubin, blood in urine by collecting spontaneous urine and analyzing with urine strips between t0 and t6 - Resting energy expenditure (REE) and macronutrient proportions in energy metabolism via indirect calorimetry before the intervention days and once per intervention day

Countries

Germany

Contacts

Public ContactTobias Fischer

FH Münster

tobias.fischer@fh-muenster.de+49251 8365444

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026